



# ARTEMIS

The Power of Virtual Twins to Fight MASLD

## D1.5 – Record of dissemination and communication actions undertaken in the previous 24 months, and updated plan

**Project Full Title:** *AcceleRating the Translation of virtual twins towards a pErsonalised Management of steatotic liver patients*

**Project acronym:** ARTEMIS

**Project type:** Horizon Europe | RIA (Topic HORIZON-HLTH-2023-TOOL-05-03)

**Grant agreement no:** 101136299

### Document information:

|                                           |                                                                                                                 |
|-------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| <b>Deliverable no.</b>                    | <b>1.5</b>                                                                                                      |
| <b>Title</b>                              | <b>Record of dissemination and communication actions undertaken in the previous 24 months, and updated plan</b> |
| <b>Work Package</b>                       | WP1                                                                                                             |
| <b>Dissemination level</b>                | Public                                                                                                          |
| <b>Nature</b>                             | Report                                                                                                          |
| <b>Responsible partner</b>                | Marko KORENJAK                                                                                                  |
| <b>Main Contact person</b>                | Veronika VŠETÍČKOVÁ                                                                                             |
| <b>Deliverable due submission date</b>    | Month 24                                                                                                        |
| <b>Deliverable actual submission date</b> | Month 24                                                                                                        |

### Document validation:

| <b>Validated by</b> | <b>Name</b>         | <b>Organisation short name</b> | <b>Visa</b> |
|---------------------|---------------------|--------------------------------|-------------|
| <b>Responsible</b>  | Veronika VŠETÍČKOVÁ | ELPA                           | OK          |
| <b>Reviewer 1</b>   | Amelia SUAREZ       | MATICAL                        | OK          |

|                   |                    |     |    |
|-------------------|--------------------|-----|----|
| <b>Reviewer 2</b> | Domenico De Santis | ULS | OK |
|-------------------|--------------------|-----|----|

### Disclaimer

The opinions stated in this report reflect the opinion of the authors and not the opinion of the European Commission.

All intellectual property rights are owned by the consortium of ARTEMIs under terms stated in their Consortium Agreement and are protected by the applicable laws. Reproduction is not authorised without prior written agreement. The commercial use of any information contained in this document may require a license from the owner of the information.

### History of changes:

| Change explanation | Pages affected | Change made by (Name & surname) | Date |
|--------------------|----------------|---------------------------------|------|
|                    |                |                                 |      |
|                    |                |                                 |      |

## Table of Contents

|                                   |           |
|-----------------------------------|-----------|
| <b>INTRODUCTION.....</b>          | <b>3</b>  |
| <b>1. Legal basis.....</b>        | <b>3</b>  |
| <b>2. Digital presence .....</b>  | <b>3</b>  |
| 2.1 ARTEMIs website.....          | 4         |
| 2.2 Scientific publications.....  | 10        |
| 2.3 Social media presence .....   | 11        |
| 2.4 Social media - analytics..... | 15        |
| <b>3. Physical presence .....</b> | <b>17</b> |
| 3.1 Informative materials.....    | 17        |
| 3.2 Promotional materials.....    | 20        |
| 3.3 Events.....                   | 21        |
| <b>4. CONCLUSION .....</b>        | <b>29</b> |

# INTRODUCTION

The primary goal of this deliverable is to outline the communication tools and materials developed by ARTEMIs partners, under ELPA's guidance, over the past year to reach the different target groups.

This annual report summarises the dissemination and communication activities undertaken in the previous 24 months by the Consortium members.

The target segment of patients and the civil society is of particular interest. This deliverable also compiles actions targeted to project's followers and civil society, informed and involved by sharing the project's achievements and their significance. To ensure accessibility, both the language and format of these materials have been carefully tailored to meet the needs of this audience.

The key objectives of Communication and Dissemination Work Package include:

- Bridging the gap between scientific, commercial, and patient-centered information;
- Increasing public awareness;
- Translating scientific findings into commercially relevant insights for stakeholders;
- Informing patients and the public about the study's progress;
- Sharing results in both traditional and online formats, aimed at commercial, medical, and patient audiences.

## 1. Legal basis

The project is funded by the Horizon Europe programme of the European Union (EU), aligned with Grant Agreement No. 101136299. Both the Grant Agreement and Consortium Agreement hold authority over this document, with the Grant Agreement taking precedence in all situations.

## 2. Digital presence

In EU research initiatives, a strong digital presence is indispensable. It embodies transparency, accessibility, and collaboration, creating a network that connects researchers, patients, policymakers, and the general public.

At the foundation of this digital landscape are the principles of openness and accessibility. By leveraging dedicated websites, social media, and online databases, EU research projects make information available to the public and interested stakeholders, ensuring that updates on current programs, progress, and key data are easily accessible. This openness fosters an inclusive environment where anyone can explore the latest research developments in detail.

A robust digital presence also facilitates the effective dissemination of essential information. Findings, publications, and breakthroughs can be shared promptly across multiple digital platforms, not only educating the audience but also encouraging collaboration and innovation within the research community. This real-time sharing sparks dialogue and feedback, advancing the collective pursuit of knowledge.

Beyond academia, a strong digital presence empowers patients and the general public by offering understandable insights into complex scientific topics. Accessible language, interactive content,


and multimedia simplify research, helping individuals make informed decisions and increasing awareness of health-related issues. This aspect promotes public health literacy, creating a more informed society that engages with ongoing research.

Moreover, an effective digital presence enhances visibility and support. Showcasing success stories, impactful outcomes, and the societal importance of research draws attention from a wide range of stakeholders, emphasizing the value of these initiatives and boosting their potential for positive change.

The adaptability of digital platforms also supports the evolution of EU research projects. Integrating new technologies, interactive features, and multimedia ensures that these initiatives stay relevant, responsive to emerging needs, and capable of engaging diverse audiences effectively.

## 2.1 ARTEMIs website

The ARTEMIs website ([artemis-euproject.eu](https://artemis-euproject.eu)) has been launched in July 2024 and has accumulated 6872 individual visitors, and 15,108 visits in its first year. The website is used as the primary platform for public communication, dissemination, and engagement. It hosts essential information, project updates, results, scientific publications, public deliverables, and other reports generated by the project. The website also serves as a comprehensive knowledge center for all stakeholders. Visitors can learn about the project's objectives and methodology, explore the various work packages, and find a list of all ARTEMIs' partners. Downloadable resources and explanatory materials are already available to the public, with additional resources to be added as the project advances.




### Dedicated

### Patient

### Section:


Acknowledging the essential role of patients, ARTEMIs offers a section specifically designed for them. This space provides accessible information, helpful resources, and relevant updates to support and empower patients and their families throughout their journey.



## Events

## Space:

A dedicated section features an overview of upcoming workshops, seminars, and conferences. These events provide valuable opportunities for knowledge sharing among researchers, healthcare professionals, patients, and other stakeholders.



ARTEMIS website is also shared on the ELPA website, in the EU Research projects section:



In 2023, ELPA web page traffic counted more than a million visitors.






In 2025, the project website underwent a series of substantial updates aimed at improving its accessibility, usability, and overall coherence for a broader public audience. Several content sections were reorganised and, where appropriate, merged to create a more streamlined and intuitive navigation structure, resulting in a menu that is clearer and more user-friendly.




All descriptions of the project's Use Cases were reviewed and updated to accurately reflect the latest progress and results achieved within each work stream.



Use Case 1 – Fibrosis progression in MASLD patients



Use Case 2 – Fibrosis-associated heart failure patients




Use Case 3 – Cardiovascular complications after TIPS placement (Portal Hypertension) or liver transplant




Use Case 4 – Prediction of cardiac complications due to HCC treatments

The “**Events**” page underwent a complete redesign, now featuring three newly created subsections that facilitate easier access to the Consortium meetings page, the Events page, and the News about the project. To further enhance user experience, background colours and visual contrasts across the website were adjusted to improve readability and ensure greater comfort for visitors.



Collectively, these updates significantly strengthened the clarity, accuracy, and accessibility of the website, ensuring it continues to serve as a reliable and engaging platform for disseminating project information to stakeholders and the general public.

Keeping patients at the center of the ARTEMIS project is deeply ingrained in the project's values, which is why the Patients' corner also got improved. Three statements from ELPA's Board members and a video from Marko Korenjak were added, explaining the way ARTEMIS and its use of the Virtual Twins is bringing new hope in the patient community living with MASLD. A flyer was also developed, explaining the ARTEMIS' project in layperson's terms. <https://artemis-euproject.eu/patients-corner/>



ARTEMIS Project – A New Hope for Liver Health

What Is the ARTEMIS Project?

ARTEMIS (Accelerating the Translation of virtual twins towards a personalized Management of fatty liver patients) is a 4-year European research initiative. It aims to support people with fatty liver disease (MASLD) by developing cutting-edge digital tools known as virtual human twins.

Why It Matters for Patients

- MASLD affects 1 in 4 people in Europe.
- It can silently progress to liver inflammation, cirrhosis, or cancer.
- It is often connected to heart problems.
- Early detection and personalized care can change the story.

How Patients Will Benefit

- Personalized care plans tailored to your health profile
- Early detection of risks before serious damage occurs
- Clear explanations and lifestyle guidance from your doctor
- Peace of mind knowing your care is proactive, not reactive

What Is a "Virtual Twin"?

A virtual or digital twin is like a virtual copy of your body's organs (in this case essentially your liver and heart).

- It's built from your real health information: scans, lab results, blood pressure, lifestyle data.
- Doctors and researchers use it to safely "test out" what might happen inside your body — without any risk to you.
- For example, it can show how your heart might react to liver treatments or what could happen if your condition worsens.

Think of it like a flight simulator for your health: just as pilots train on simulators before flying real planes, doctors can use your digital twin to understand your health better before making decisions.

How It Works – The Mechanism

- Virtual Twins:** A safe digital model of your organs, created using data from many people — but personalized with your own information.
- AI + Medical Knowledge:** Smart predictions about how your condition may progress.
- Smart Dashboard for Doctors:** Helps guide the best treatment or lifestyle plan for you.

WHAT'S THE PROJECT?

A European research effort developing "virtual twins" to fight fatty liver disease.

WHY IT MATTERS

Fatty liver is common, dangerous, and touches more people. Personalized care can help.

BENEFITS FOR PATIENTS

Tailored care, early warnings, clearer choices, better health understanding.

HOW IT WORKS

Combines your health data + AI to create a digital twin for smarter decisions.

Is This New and Can I Trust It?

**Proven concept:** Virtual twins are already being used in areas like heart surgery planning and cancer research. Now, the ARTEMIS project is using this same technology to better understand and treat liver disease and heart problems.

**Safety first:** Your digital twin is only a virtual model—it does not replace your body or make decisions on its own.

**Doctor in control:** The digital twin is a support tool. Your doctor will always be the one making medical decisions.

**Privacy protected:** The project follows strict European data protection laws (GDPR), meaning your personal data is safe and handled responsibly.

**Science-backed:** ARTEMIS involves leading hospitals, universities, and patient groups across Europe—so the project is built on trusted medical research.

Bottom line: The digital twin is a new tool to help doctors help you. It's not replacing human care, but making it smarter, safer, and more personalized.

Patient Voices – Why ARTEMIS Matters

“When I was first told I had MASLD, I felt scared and lost. The ARTEMIS project gives me hope because it's working toward helping doctors understand my health story more clearly—not just numbers on a paper. I look forward to a future where care feels truly about me, not just my disease.”

María, 52 – Living with MASLD

“I already deal with heart issues, and now my liver is also affected. What inspires me about ARTEMIS is that it aims to help doctors see how my liver and heart are connected. Knowing that their kind of innovation is being developed makes me feel safer—because one day it could help catch problems before they get worse.”

David, 45 – Managing Heart and Liver Issues

“I love the idea behind ARTEMIS—creating a kind of 'virtual twin' to better understand our health. It's still in progress, but if it can help doctors explain things more clearly and show what lifestyle changes truly make a difference, I'm all in. It gives me hope and makes me feel more in control of my future.”

Elena, 40 – Caring for Her Health Proactively

Frequently Asked Questions (FAQ)

Will this replace my doctor?

No. The digital twin is a support tool. Your doctor remains in charge of your care.

Is my data safe?

Yes. ARTEMIS follows strict European data protection laws (GDPR). Personal information is kept private and secure.

When will this be available?

The project runs from 2024 to 2028. Results will be tested in real-world clinics after the research phase.

The ARTEMIS Project is bringing the future of healthcare to today's patients—making care personalized, proactive, and empowering for everyone living with MASLD.

The ARTEMIS website is regularly consulted with 14,600 individual visitors and 91,900 views in 2025, showing an impressive growth compared to the previous year.

| Traffic Summary       |          |       |
|-----------------------|----------|-------|
| ● Online Visitors     |          |       |
| 1                     |          |       |
| Time                  | Visitors | Views |
| Today                 | 33       | 157   |
| Yesterday             | 26       | 270   |
| This week             | 140      | 1.11K |
| Last week             | 197      | 1.93K |
| This month            | 911      | 7.94K |
| Last month            | 1.29K    | 8.47K |
| Last 7 days           | 210      | 1.95K |
| Last 30 days          | 1.05K    | 8.9K  |
| Last 90 days          | 4K       | 30.1K |
| Last 6 months         | 8.55K    | 73K   |
| This year (Jan-Today) | 8.55K    | 73K   |
| Total                 | 14.6K    | 91.9K |

9

This document is a deliverable of the ARTEMIS project. The ARTEMIS Project is funded by the European Union within the Horizon Europe program under grant agreement No 101136299.

## 2.2 Scientific publications

Below are all the publications released under the ARTEMIs project.



| Title                                                                                                                          | Authors                                                                    | Title of the journal/ Proceeding s/ Books series/ Book (for book chapters) | Link                                                                                                                                        | Year |
|--------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|------|
| Steatotic liver disease and HIV: an agenda for 2030                                                                            | Juan M. Pericàs, J. M., Anish K Arora, Carlotta Riebensahm, et al.         | The Lancet HIV                                                             | <a href="https://doi.org/10.1016/S2352-3018(24)00097-3">https://doi.org/10.1016/S2352-3018(24)00097-3</a>                                   | 2024 |
| On the different flavours of practical identifiability                                                                         | Mio Heinrich, Rafael Arutjunjan, Jens Timmer                               | Current Opinion in Systems Biology                                         | <a href="https://doi.org/10.1016/j.coisb.2025.100556">https://doi.org/10.1016/j.coisb.2025.100556</a>                                       | 2025 |
| Call to action to address the steatotic liver disease public health threat in Barcelona                                        | Jeffrey V Lazarus, J Emilio Miralles-Sanchez, Leire Agirre-Garrido, et al. | The Lancet Regional Health – Europe                                        | <a href="https://linkinghub.elsevier.com/retrieve/pii/S266677622500064X">https://linkinghub.elsevier.com/retrieve/pii/S266677622500064X</a> | 2025 |
| Comparison of Bacterial Infections in Patients With Cirrhosis Between Hospitals With and Without Liver Transplant in Catalonia | Clàudia Torras, J Juan Bañares, Aina Martí-Carretero, et al.               | Liver international                                                        | <a href="https://doi.org/10.1111/liv.70076">https://doi.org/10.1111/liv.70076</a>                                                           | 2025 |
| Cell Homeostasis or Cell Death—The                                                                                             | Stilkerich, A., Schicht, G., Seidemann, L., et al.                         | Cells                                                                      | <a href="https://doi.org/10.3390/cells14060449">https://doi.org/10.3390/cells14060449</a>                                                   | 2025 |


|                                                                                                                |                                               |              |                                                                                                       |      |
|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------|--------------|-------------------------------------------------------------------------------------------------------|------|
| Balancing Act Between Autophagy and Apoptosis Caused by Steatosis-Induced Endoplasmic Reticulum (ER) Stress    |                                               |              |                                                                                                       |      |
| Stage-dependent Effects of Systemic ASBT Inhibition in a Cholestasis-induced Cholemic Nephropathy Mouse Model. | Ghallab, A., Myllys, M., González, D., et al. | JHEP Reports | <a href="https://doi.org/10.1016/j.jhepr.2025.101599">https://doi.org/10.1016/j.jhepr.2025.101599</a> | 2025 |

## 2.3 Social media presence

The ARTEMIS projects owns social media accounts, such as X (still open but not updated since April 2025 due to a consortium decision) LinkedIn [ARTEMIS - The Power of Virtual Twins to Fight MASLD](#) (355 followers), and Bluesky [@artemis-euproject.bsky.social](#) (opened as an alternative to X)

Those social media accounts are mainly used to publish updates on project progress and share important insights relevant to our followers in a language that is easily understandable by the general public.





ARTEMIS' social media accounts are also used to post ambitious social media campaigns explaining the project with more details.


### 2.3.1 Social Media Campaign – ARTEMIS' partners

Starting at the end of the year 2024, ELPA developed 21 posts about the ARTEMIS project partners that were disseminated on LinkedIn and X. Visuals that incorporated the ARTEMIS' graphic style were created, with the inclusion of the logo of the partner and the country they are based in, to increase interest of the public in the ARTEMIS project and its partners.



## 2.3.2 Social Media campaign – Facts about the project



A second social media campaign was disseminated at the same time, consisting of 19 informative posts about the ARTEMIS project to increase visibility and curiosity of the general population.



## 2.3.3 Social Media campaign – ELPA Board members

In 2025, ELPA launched a targeted social media campaign aimed at highlighting the central role of patients within the project. The campaign featured a series of visuals built around quotes from members of ELPA's Board, each emphasising patient perspectives, lived experience, and the added value that patient involvement brings to European research initiatives. By amplifying these voices, ELPA aimed to reinforce the message that patient-centred approaches are a defining strength of the project.


In addition to being shared on ELPA's social media channels, these materials were integrated into the "Patients' Corner" section of the project website, ensuring sustained visibility and providing a dedicated space where patient representatives and the wider public can engage with the project's values and priorities.



## 2.3.4 ARTEMIs on other partners' social medias

ARTEMIs' partners also contributed in promoting the project through social media.

*Medexprim/BC Platforms* shared a few LinkedIn posts about the ARTEMIs project, notably on the launch of the project at the beginning of 2024, as well as a couple reposts from other partners. The BC Platforms website with an ARTEMIs section in the EU Consortia page was also launched in 2024.



## ARTEMIs

AcceleRating the Translation of virtual twins towards a pERsonalized Management of fatty liver patients

ARTEMIs is a four-year research project, aiming to co-design and develop a POC of a Clinical Decision Support System (CDSS)—a cutting-edge clinical visualization tool—offering an overview of patient multimodal data and therapeutic decision-aid, thanks to the integrated virtual twin models. The CDSS provides dynamic and multilevel representations of tissues and organs and will provide support to clinicians to achieve early diagnosis, prediction of disease evolution, assessment of cardiovascular outcomes, and guidance towards specific treatments or interventions. This will mark a significant leap forward in MAFLD patient's healthcare.


Medexprim, member of BC Platforms Group, is the architect and a proud participant of ARTEMIs.

This project has received funding from the European Union within the Horizon Europe program under grant agreement N° 101136299.

Learn more about [ARTEMIs](#).



In 2025 as well, ARTEMIs partners participated in promoting the ARTEMIs project on social media, by posting their original content, or by reposting other partners' content.



## 2.4 Social media - analytics

**X in project year 1:** Since the creation of ARTEMIS' X account, the follower count went from 0 to 55 followers, demonstrating strong growth for a new presence. In total, the ARTEMIS X account posted or reposted 71 times, accumulating 122,300 impressions, reflecting substantial reach and visibility. Engagement metrics show a total of 177 likes and 160 retweets. The most engaged hashtags were #MASH, #MASLD, and #LIVERCANCER, indicating the content resonated well with communities around these topics.

**LinkedIn in project year 1:** Starting at 0, the account grew to 253 followers/connections, showing impressive growth within a professional network. LinkedIn's 57 posts achieved a total of 26,261 impressions, highlighting robust content visibility. LinkedIn posts saw significant interaction with 858 combined reactions, 33 comments, 27 reposts, and 2,433 clicks. In total, ARTEMIS' posts reached 13,738 members, showcasing meaningful outreach within the platform's audience.

# The #LiverCancerAwarenessMonth Influencers

## Top 10 Influential

|                                                                                   |                    |
|-----------------------------------------------------------------------------------|--------------------|
|  | @liverationEU 81   |
|  | @HorizonARTEMIS 64 |
|  | @EU_HaDEA 59       |

9:35 5G 44%

## New follower metrics

D1.5

Last 30 days

|    |                                                                                      |                                                                                         |                |
|----|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|----------------|
| 1  |    | Hospital Universitari Vall d'Hebron<br>58,332 total followers                           | 719<br>▼ 17.2% |
| 2  |    | Cliniques universitaires Saint-Luc<br>23,850 total followers                            | 341<br>▼ 5%    |
| 3  |    | World Obesity Federation<br>12,630 total followers                                      | 233<br>▲ 13.7% |
| 4  |    | PAINLESS Horizon Europe Project<br>1,099 total followers                                | 77<br>▲ 8.5%   |
| 5  |    | Le sport est essentiel<br>4,416 total followers                                         | 41<br>▼ 29.3%  |
| 6  |    | JaxCareConnect<br>581 total followers                                                   | 33<br>▲ 200%   |
| 7  |    | ARTEMIs - The Power of Virtual Twins to Fight MASLD<br>Your Page<br>253 total followers | 18<br>▼ 51.4%  |
| 8  |    | The CHAIMELEON Project<br>661 total followers                                           | 18<br>0%       |
| 9  |  | ProCancer-I project<br>766 total followers                                              | 14<br>▲ 7.7%   |
| 10 |  | RadioVal<br>408 total followers                                                         | 7<br>▼ 61.1%   |

*X / Bluesky in project year 2:* In 2025, the ARTEMIs Consortium decided to forego the Twitter/X account, which had grown from 55 to 161 followers, and open a Bluesky account instead in April. In November, the Bluesky account shows a growth of 9 followers in 2025. Continuous efforts will be made to increase the following on Bluesky in 2026.

*LinkedIn in project year 2:* The LinkedIn account shows a steady growth in 2025. It went from 253 followers/connections to 355. In total for the year, ARTEMIs' posts on LinkedIn generated 10,880 impressions, 376 reactions, 10 comments, and 5 reposts. In 2026, effort will be renewed to improve engagement on all ARTEMIs' platforms.

## Location


|                                                           |
|-----------------------------------------------------------|
| Greater Paris Metropolitan Region, France • 39<br>(11.3%) |
| Brussels Metropolitan Area, Belgium • 12 (3.5%)           |
| Greater Toulouse Metropolitan Area, France • 12<br>(3.5%) |
| Rhein-Neckar Metropolitan Region, Germany • 9<br>(2.6%)   |
| London Area, United Kingdom, United Kingdom • 8<br>(2.3%) |

## Total post metrics

Last 30 days

|   |                                                                                      |                                                                  |               |
|---|--------------------------------------------------------------------------------------|------------------------------------------------------------------|---------------|
| 1 |  | Hospital Universitari Vall d'Hebron                              | 93<br>▲ 12%   |
| 2 |  | World Obesity Federation                                         | 21<br>▼ 22.2% |
| 3 |  | RadioVal                                                         | 15<br>▲ 36.4% |
| 4 |  | PAINLESS Horizon Europe Project                                  | 11<br>▼ 31.3% |
| 5 |  | ARTEMIs - The Power of Virtual Twins to Fight MASLD<br>Your Page | 10<br>▲ 25%   |






### 3.Physical presence

#### 3.1 Informative materials

Informational materials like booklets and flyers are invaluable resources for any EU project, providing clear, accessible summaries of complex research, objectives, and outcomes. These tools effectively engage diverse audiences—including stakeholders, policymakers, researchers, and the public—by presenting a tangible overview of the project. Booklets offer in-depth insights into the project's goals, methods, and accomplishments, while flyers serve as concise visual aids that capture attention and communicate key messages efficiently. Together, these materials enhance visibility and understanding, broadening the project's outreach and conveying its importance and impact on society.

##### 3.1.1 ARTEMIS' project brochure

A brochure introducing the ARTEMIS project was written, highlighting the project's dedication to combating Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by developing innovative tools like virtual twin models and a Smart Dashboard. The brochure also highlights the project's scope, including the collaboration across nine countries, the cohort of 7,500 patients, and the integration of cutting-edge computational models. It outlines ARTEMIs' commitment to improving patient outcomes and fostering precision medicine for liver health.



### Understanding MAFLD Progression: A Gateway to Effective Management


Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD) now dominates chronic liver disease (CLD) in Europe, surpassing viral hepatitis and alcohol-related causes, with a prevalence exceeding **25%**. This rise is linked to escalating risk factors from unhealthy lifestyles. MAFLD's diverse clinical trajectory, including **steatosis, NASH, cirrhosis and hepatocellular carcinoma**, stems from varied underlying mechanisms. In particular, the inflammatory facet - non-alcoholic steatohepatitis (**NASH**) - heightens **cardiovascular disease (CVD)** risk, a leading cause of death in MAFLD patients. Understanding MAFLD progression and the liver-heart axis is crucial for effective management. This consortium will develop **liver and heart computational models and virtual twins**, offering insights into heart/liver functions across different stages of the disease.




### Empowering Precision Healthcare with ARTEMIS

ARTEMIS aims to co-design and develop a proof-of-concept (POC) of a Smart Dashboard—a cutting-edge clinical decision support system offering an overview of patient multimodal data and therapeutic decision-aid, thanks to the integrated virtual twin models. From early diagnosis to predicting disease evolution, assessing cardiovascular outcomes, and guiding specific treatments or interventions, the Smart Dashboard provides dynamic, multilevel representations of tissues and organs. This approach empowers clinicians to implement personalized and responsive care strategies, marking a significant leap forward in MAFLD patient management.

The project will focus on 4 clinical cases, each one addressing a stage of the MAFLD progression:



A second brochure was also published, providing an overview of the **ARTEMIS Clinical Use Cases**, showcasing the project's four key focus areas for improving the management of MASLD and associated conditions. Each use case is explained in detail, highlighting its primary and secondary objectives, inclusion and exclusion criteria, and expected outcomes. Through these use cases, the brochure emphasizes the application of virtual twin models and advanced computational tools to support clinicians in personalizing treatment and improving outcomes for patients.



**PRIMARY OBJECTIVE**

Evaluate the model's ability to distinguish patients based on their time to progression between subsequent phases of liver fibrosis and clinical phenotypes

**SECONDARY OBJECTIVES**

- Evaluate the model's ability to distinguish patients based on their **time to mortality**
- Evaluate the model's ability to distinguish patients based on their **time to liver transplantation**
- Evaluate the model's ability to distinguish patients based on their **time to liver decompensation**
- Evaluate the model's ability to distinguish patients based on their **time to hepatocellular carcinoma**

**EXPLORATORY OBJECTIVES**

- Better understanding of **mechanism of actions of specific therapeutic interventions for obesity, T2DM or cardiovascular diseases** prevention and their impact on liver fibrosis
- Evaluation of the **impact of lifestyle modifications and treatments on fibrosis stage progression**
- Measurement of **demographic, clinical, biochemical** (fibrosis stage assessment: fibroscan, liver histology, sheenwave elastography, validated biomarkers scores such as FIB4 (<https://www.hepatolibrary.com/page/clinical-calculators/fib-4>) associated to progression of liver fibrosis in a large cohort of patients with MAFLD

**PRIMARY OUTCOME/MEASURE**

Time to progression between subsequent phases of liver fibrosis, based on the Fib-4 algorithm  
| Time frame: 5-7 years

**SECONDARY OUTCOME/MEASURES**

- Measurement of median mortality rate | Time frame: 5 years
- Measurement of time to liver transplantation | Time frame: 5 years
- Measurement of time to liver decompensation | Time frame: 5 years
- Measurement of time to diagnosis of hepatocellular carcinoma | Time frame: 5 years
- Occurrence of non-liver cancer events | Time frame: 5-7 years

**EXPLORATORY ENDPOINT**

- Time to progression between subsequent phases of liver fibrosis, based on the Fib-4 algorithm
- Non-invasive biomarkers of the presence of and severity of cardiac fibrosis through metabolomics and/or analytical biomarkers | Time frame: 5 years - liquid biopsy

**Fibrosis progression in MAFLD patients Objectives & Outcomes**

### 3.1.2 ELPA's brochure

ELPA also made sure to include ARTEMIs in the "ELPA Scientific Booklet", which is a brochure presenting all European projects ELPA is currently supporting. The brochure reflects ELPA's mission to enhance patient care, promote research, and provide a bridge between the scientific community, policymakers, and patients. It highlights ARTEMIs as one of many innovative projects demonstrating ELPA's commitment to fostering collaboration and advocating for equitable and effective healthcare solutions for liver patients. This brochure is disseminated during congresses ELPA participates in, or events organised by ELPA.



**ARTEMIs**

Accelerating the Translation of virtual twins towards a personalised Management of fatty liver patients

The ARTEMIs project aims to consolidate existing computational mechanistic and machine-learning models at different scales to deliver virtual twins embedded in a clinical decision support system (CDSS). The CDSS will provide clinically meaningful information to clinicians, for a more personalised management of the whole spectrum of Metabolic Associated fatty Liver Disease (MAFLD), MAFLD, with an estimated prevalence of about 20%, goes from an undetected sleeping disease, to inflammation (steatosis), to fibrosis development (portal hypertension, hepatocellular carcinoma (HCC), decompensated cirrhosis and HCC being the final stages of the disease. However, many MAFLD patients do not die from the liver disease itself, but from cardiovascular comorbidities or complications.

The ARTEMIs will contribute to the better management of MAFLD patients, by progressing the development of more advanced forms of the disease and cardiovascular comorbidities, promoting active surveillance of patients at risk. The system will predict the impact of novel drug treatments or procedures, or simply better life habits. The system will therefore not only serve as a clinical decision aid tool, but also as an educational tool for patients, to promote better nutritional and lifestyle behaviors. In more advanced forms of the disease, therapeutic interventions include TIPS to manage portal hypertension, partial hepatectomy, partial or complete liver transplant. ARTEMIs will contribute to predict pre- or post-intervention heart failure, building on existing microcirculation hemodynamics models. The model developers will benefit from a large distributed patient cohort and data exploration environment to identify patterns in data, draw new theories on the liver heart metabolic axis and validate the performance of their models. The project includes a proof of concept feasibility study assessing the utility of the proposed virtual twins and CDSS in the clinical context.

**Grant agreement ID**  
101136299

**Start date**  
1 January 2024

**End date**  
31 December 2027

**Funded under**  
HORIZON-EL-1.1.5


**Overall budget**  
€ 9 340 000,00

**EU contribution**  
€ 9 340 000,00

**14**

## 3.2 Promotional materials

To mark the kick-off meeting of the **ARTEMIS project**, a range of promotional materials were developed to enhance visibility and foster engagement. These materials included branded notebooks, pens, and banners, all designed to reflect the project's identity and mission. The items were distributed during the kick-off meeting, serving as both practical tools and reminders of the project's goals. The banners prominently showcased the ARTEMIS logo, partners and key messaging, ensuring a professional and cohesive presence throughout the meeting. These efforts underscored the commitment to building a strong, recognizable brand for the project from its inception.



## 3.3 Events

### 3.3.1 ARTEMIs Consortium events

#### Kick-off meeting – 6<sup>th</sup> February 2024, Paris

The ARTEMIs project kick-off meeting was held on the 6<sup>th</sup> of February 2024. This meeting took place in the PariSanté Campus in Paris, France. Representatives from all 21 partner institutions were present to the meeting, all united with the will to massively improve the management of MASLD.

The meeting started with a welcome speech, presenting ARTEMIs governance, the clinical cases, and the consortium members, led by the project officer and various leaders. The introductory session was followed by a presentation on administrative tasks, an overview of timelines, reporting procedures, and compliance under Horizon Europe.

The afternoon sessions were on more specific topics, such as fibrosis and MASLD evolution, cirrhosis and cardiac complications, and hepatocellular carcinoma challenges. To follow these sessions, a team of modelers and clinicians identified transversal actions and specific strategies.

To close, the outcomes of the kick-off meeting were summarized into actionable steps for the next six months, followed by brainstorming and a welcome dinner to encourage networking among the different partners.



#### ARTEMIs Consortium meeting – 26<sup>th</sup> and 27<sup>th</sup> September 2024, Barcelona

Taking place on the 26<sup>th</sup> and 27<sup>th</sup> of September in Barcelona, Spain, the ARTEMIs Consortium meeting was hosted by the Vall d'Hebron Institute for Research.

### *Day 1: Clinical focus*

The day started with an opening session, with welcoming remarks and an overall project overview, followed by discussions on ARTEMIs cohorts, use cases, and data availability. A **clinical workshop** then took place, with sessions focusing on MASLD, including its pathophysiology, natural history, diagnosis, monitoring, and management. The day ended with key takeaways, discussions on integrating clinical insights, imaging, and management strategies for MASLD progression.

### *Day 2: Technical and collaborative focus*

The second day opened with technical sessions, discussions on data infrastructure, processing pipelines, and compliance with ethical and legal standards. Tools for data extraction and harmonization were also presented. An introduction on model development also took place, with a focus on machine learning, deep learning submodels, and integration techniques for liver and cardiac interactions.

The day ended with conclusive remarks and a general wrap-up with critical action points and a roadmap for the next year.



### **ARTEMIs Consortium meeting – 1<sup>st</sup> and 2<sup>nd</sup> of April 2025, Heidelberg**

The ARTEMIs Consortium held its third Consortium Meeting, combined with the second Clinical Workshop, on 1–2 April 2025 at the BioQuant Center in Heidelberg. Hosted by the German Cancer Research Center (DKFZ), the two-day event gathered project partners from clinical, academic, and industry institutions across Europe to review progress, exchange insights, and refine the project's scientific and strategic direction.

The first day of the meeting had “Scientific Progress and Clinical Insights” for theme. The meeting opened with a welcome session and project overview delivered by Ursula Klingmüller (DKFZ) and Laura Muñoz (MAT), followed by a comprehensive update on the status of the project's four clinical use cases.

An update on the ARTEMIs Cohort was then presented by VHIR and MEDEX-BCP, covering patient recruitment, data collection updates, and monitoring procedures related to the project's prospective study.

In the afternoon, the consortium gathered for the Clinical Workshop on "The Role of the Heart-Liver Axis in MASLD." The workshop highlighted the importance of integrating clinical expertise, imaging data, and computational tools to advance personalised diagnostics for MASLD.

On the second day, the focus was on "Coordination, Infrastructure, Modelling and Implementation". The day opened with updates on project coordination, legal compliance, data protection, and communication activities. The session also emphasised upcoming priorities ahead of the first project review and underlined the importance of dissemination, regulatory alignment, and patient engagement.

During the afternoon, the second use case working session enabled teams to consolidate action plans, followed by a dedicated block on exploitation, regulatory considerations, sustainability planning, and pathways to future adoption of ARTEMIs tools.



### 3.3.2 Scientific conferences and workshops

#### European Virtual Human Twins Initiative: Advancing AI-driven, Patient-Centred Healthcare in Europe- October 2025

On the 21<sup>st</sup> and 22<sup>nd</sup> of October 2025, INRIA and Laura Muñoz were invited to the European Commission's high-level event to advance the strategic vision of the **European Virtual Human**

**Twins (VHT) Initiative** and present the ARTEMIs project. This initiative is a flagship effort launched in December 2023 to accelerate the development and uptake of next-generation virtual human models in health and care. The initiative supports EU priorities in artificial intelligence, supercomputing, and health data infrastructure, and it has already gathered strong momentum, with more than **90 organisations** endorsing the European VHT Manifesto.

The event brought together a wide range of stakeholders—including policymakers, researchers, clinicians, industry representatives, and patient organisations—to discuss how VHT technologies can be effectively integrated into clinical practice and contribute to personalised medicine.



### EASL Congress – May 2025

In 2025, EASL took place from the 7<sup>th</sup> to the 10<sup>th</sup> of May 2025, in Amsterdam, in the Netherlands.

This year again, ELPA gathered 40 dedicated patient advocates, ELPA members from across Europe, to the EASL Congress, representing the largest European liver patient community. Throughout the Congress, participants celebrated shared achievements, addressed ongoing challenges, and strengthened collaboration with leading scientific, academic, and industry partners, all with the common goal of advancing best practices, innovation, and improved liver health across Europe.



| Partner | Type of activity                 | Type of activity & Title of dissemination                                                    | Name of event                                                                                                                             | Place, Country          | Date (DD/MM/YYYY)         | Type of audience reached          | Estimated Number of persons reached |
|---------|----------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|---------------------------|-----------------------------------|-------------------------------------|
| BETT    | Workshop attendance/organisation | Workshop presentation                                                                        | Workshop on Medical Device Regulation Course                                                                                              | Ostrava, Czech Republic | 13th-14th January 2024    | Research communities              | 20                                  |
| BETT    | Workshop attendance/organisation | Workshop presentation                                                                        | Digital Pioneering in Healthcare                                                                                                          | Prague, Czech Republic  | 6th February 2024         | Research communities              | 30                                  |
| BETT    | Conference poster                | Poster on the conference                                                                     | Prague Bio Conference 2024                                                                                                                | Prague, Czech Republic  | 26th September 2024       | Research communities              | 100                                 |
| BETT    | Trade fair                       | Attendance with the booth at fair trade                                                      | COMPAMED 2024                                                                                                                             | Dusseldorf, Germany     | 11th - 14th November 2024 | Industry, business partners       | 25000                               |
| MEDEX   | Webinar                          | Oral presentation during a webinar                                                           | Webinar "Santé Numérique : Opportunités Horizon Europe 2025" (Digital Health : Horizon Europe 2025 Opportunities), organized by EurBioMed |                         | 02/06/2025                | Research communities and Industry | 80                                  |
| ALL     | Conference poster                |                                                                                              | Poster at the EDITH Amsterdam meeting                                                                                                     |                         | 15-16 July 2024           | EU institutions                   |                                     |
| BU      | Conference papers/proceedings    | Keynote speech: A Short Overview of AI in Systems Medicine: Multi-omics integration and more | The 9th Conference on Systems Medicine & Mammal Cell Biology                                                                              | Leipzig, Germany        | 13-15 May 2024            | Research communities              | 100                                 |
| INRIA   |                                  | Course presentation                                                                          | Master UE Bioengineering, Sorbonne U.                                                                                                     | Paris, France           | 01/2025                   | Civil society                     | 30                                  |
| INRIA   |                                  | Oral presentation/discussion                                                                 | Junior High School students internship week at Inria                                                                                      | Palaiseau, France       | 20-24 January 2025        | Civil society                     | 15                                  |
| INRIA   | Workshop attendance/organisation | Spring school teaching                                                                       | Reduced order and Data Driven models in Biomechanics                                                                                      | Figueres, Spain         | 04/2025                   | Research communities              | 60                                  |

|         |                                                        |                                                                                                                                                  |                                                                                                                                                                                                                                                       |                   |                 |                      |       |
|---------|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-----------------|----------------------|-------|
| INRIA   | Press releases/<br>Articles published in popular press | Interview by Magazine Hospitalia                                                                                                                 | <a href="https://www.hospitalia.fr/SimbiotX-des-jumeaux-numeriques-au-service-de-la-decision-medicale_a4517.html">https://www.hospitalia.fr/SimbiotX-des-jumeaux-numeriques-au-service-de-la-decision-medicale_a4517.html</a> (Magazine #69 + online) | Paris, France     | 07/2025         | Citizens             | 10000 |
| INRIA   | Workshop attendance/organisation                       | Expert EU meeting                                                                                                                                | ApplyAI Strategy: Healthcare Delivery Expert Meeting                                                                                                                                                                                                  | online            | 06/2025         | EU institutions      | 50    |
| INRIA   | Workshop attendance/organisation                       | Oral presentation                                                                                                                                | Seminar of FHU Predicare                                                                                                                                                                                                                              | online            | 06/2025         | Research communities | 50    |
| INRIA   | Workshop attendance/organisation                       | Oral presentation                                                                                                                                | seminar, Computational Mechanics, IP Paris                                                                                                                                                                                                            | Palaiseau, France | 06/2025         | Research communities | 40    |
| INRIA   | Workshop attendance/organisation                       | Oral presentation                                                                                                                                | workshop on digital twins in health, French National Academy of Medicine                                                                                                                                                                              | Paris, France     | 06/2025         | National authorities | 300   |
| INRIA   | Workshop attendance/organisation                       | Keynote                                                                                                                                          | Digital Twins in Oncology symposium - PSCC Connect                                                                                                                                                                                                    | Villejuif, France | 06/2025         | Innovators           | 300   |
| DKFZ    | Conference papers/proceedings                          | Talk                                                                                                                                             | e:MED Hamburg                                                                                                                                                                                                                                         | Hamburg, Germany  | 21-23 Nov. 2024 | Research communities | 50    |
| MATICAL | Workshop attendance/organisation                       | Oral Presentation                                                                                                                                | Presentation of the Virtual Human Twins initiative by the EC                                                                                                                                                                                          |                   | 26/06/24        | Research communities | 50    |
| MATICAL | Workshop attendance/organisation                       | Oral Presentation                                                                                                                                | Virtual Human Twins HE projects Networking meeting                                                                                                                                                                                                    |                   | 08/07/2024      | Research communities | 20    |
| MATICAL | Workshop attendance/organisation                       | Oral Presentation                                                                                                                                | Horizon Europe Health Programme Committee Meeting (Cluster 1- Health)                                                                                                                                                                                 |                   | 12/12/2024      | National authorities | 200   |
| ELPA    | Leaflet distribution                                   | ELPA EU Medical Research Projects Booklet 2024, printed version, ISBN: 978-2-931120-14-9 9782931120149, distributed to ELPA members, Stakeholder |                                                                                                                                                                                                                                                       |                   | 2024            | Civil society        |       |

|      |                         |                                                                                                                                                                                                                                                                           |                                                   |                                  |                                                      |                         |                                             |
|------|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|----------------------------------|------------------------------------------------------|-------------------------|---------------------------------------------|
|      |                         | s,<br>Supporters.                                                                                                                                                                                                                                                         |                                                   |                                  |                                                      |                         |                                             |
| ELPA | Leaflet<br>distribution | ELPA EU<br>Medical<br>Research<br>Projects<br>Booklet<br>2024, e-<br>version<br>version,<br>ISBN: 978-2-<br>931120-13-2<br>9782931120<br>132,<br>distributed to<br>ELPA<br>members,<br>Stakeholder<br>s,<br>Supporters.                                                   |                                                   |                                  | 2024                                                 | Civil society           |                                             |
| ELPA | Leaflet<br>distribution | Event<br>organised by<br>ELPA to<br>promote free<br>liver<br>scanning<br>towards the<br>general<br>population in<br>front of the<br>European<br>Parliament.<br>Materials<br>distributed to<br>participants<br>presenting<br>European<br>projects<br>supported by<br>ELPA. | ELPA Screening<br>Week, October<br>2024, Brussels | Brussels,<br>Belgium             | 30th of<br>September<br>to 4th of<br>October<br>2024 | Civil society           | Around<br>400<br>people<br>were<br>screened |
| ELPA | Leaflet<br>distribution | Promotion of<br>all the<br>projects<br>supported by<br>ELPA<br>through the<br>distribution<br>of brochures<br>and<br>materials<br>presenting<br>the<br>European<br>projects                                                                                               | EASL Congress                                     | Milan, Italy                     | 5-8 June<br>2024                                     | Research<br>communities |                                             |
| ELPA | Leaflet<br>distribution | Promotion of<br>all the<br>projects<br>supported by<br>ELPA<br>through the                                                                                                                                                                                                | EASL Congress                                     | Amsterdam,<br>The<br>Netherlands | 6-9 May<br>2025                                      | Research<br>communities |                                             |

|      |                                  |                                                                                                                                                                                                                                                |                                                                                    |                         |                        |                      |             |
|------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------|------------------------|----------------------|-------------|
|      |                                  | distribution of brochures and materials presenting the European projects                                                                                                                                                                       |                                                                                    |                         |                        |                      |             |
| ELPA | Workshop attendance/organisation | Event with the theme of "Preventing Liver Cancer in the EU: Incidence, Risk Factors, and Interventions", following ELPA's screening week. Materials with all the projects supported by ELPA were distributed to the participants of the event. | ELPA's High Policy Event                                                           | Brussels, Belgium       | 20/11/2024             | EU institutions      |             |
| ELPA | Workshop attendance/organisation | Event with the theme of "Fatty liver and NCDs: A European Policy Action". Materials with all the projects supported by ELPA were distributed to the participants of the event.                                                                 | ELPA's High Policy Event                                                           | Brussels, Belgium       | 03/06/2025             | EU institutions      |             |
| VHIR | Conference poster                | Poster on the conference                                                                                                                                                                                                                       | EMIM Congress 2025 (European Congress)                                             | Spain, Bilbao           | 14/03/2025             | Research communities | Around 1200 |
| VHIR | Workshop attendance/organisation | Oral Presentation                                                                                                                                                                                                                              | 11th International Conference on Internal Medicine, Medical Association of Rosario | Argentina               | 22/05/2025             | Research communities | 250         |
| VHIR | Workshop attendance/organisation | Oral Presentation                                                                                                                                                                                                                              | Liver Seminars by CIBERehd Summer Edition 2025                                     | Barcelona               | 10/06/2025             | Research communities | 250         |
| BETT | Workshop attendance/organisation | Workshop presentation                                                                                                                                                                                                                          | Workshop on Medical Device Regulation Course                                       | Ostrava, Czech Republic | 13th-14th January 2024 | Research communities | 20          |

|      |                                  |                          |                                                          |                        |                       |                      |    |
|------|----------------------------------|--------------------------|----------------------------------------------------------|------------------------|-----------------------|----------------------|----|
| BETT | Workshop attendance/organisation | Workshop presentation    | Digital Pioneering in Healthcare                         | Prague, Czech Republic | 6th February 2024     | Research communities | 30 |
| ULEI | Workshop attendance/organisation | Oral presentation        | ScaDS.AI Leipzig/ScaDS Life-Science and Medicine Seminar | Leipzig                | 08/04/2024            | Research communities |    |
| ULEI | Workshop attendance/organisation | Oral presentation        | ECCOMAS Lissabon                                         | Lisbon                 | 3-7/06/2024           | Research communities |    |
| ULEI | Workshop attendance/organisation | Oral presentation        | Hünfeld/LiSyM retreat 2024                               | Hünfeld                | 12-13/12/2024         | Research communities |    |
| ULEI | Workshop attendance/organisation | Oral presentation        | GASL conference in Munich                                | Munich                 | 14-15/02/2025         | Research communities |    |
| ULEI | Workshop attendance/organisation | Oral presentation        | 6th Central German Bioinformatics Conference             | Leipzig                | 02-03/04/2025         | Research communities |    |
| ULEI | Workshop attendance/organisation | Oral presentation        | DZL Annual Meeting 2025                                  | Munich                 | 30/06/2025-02/07/2025 | Research communities |    |
| ULEI | Workshop attendance/organisation | Oral presentation        | Life Science Meeting at Scads.AI                         | Leipzig                | 19/06/2025            | Research communities |    |
| ULEI | Workshop attendance/organisation | Oral presentation        | Lisym Retreat in Eisenach                                | Eisenach               | 03-05/12/2025         | Research communities |    |
| ULEI | Conference poster                | Poster on the conference | Leipzig/Mittelerde Meeting 2025                          | Leipzig                | 02/04/2025            | Research communities |    |
| ULEI | Conference poster                | Poster on the conference | Düsseldorf/Status-Seminar LiSyM                          | Düsseldorf             | 08/04/2025            | Research communities |    |
| ULEI | Conference poster                | Poster on the conference | 6th Central German Bioinformatics Conference             | Leipzig                | 02-03/04/2025         | Research communities |    |

## 4. CONCLUSION

In 2024, the ARTEMIs project made substantial strides in establishing a comprehensive communication and dissemination framework to support its goals.

Building on the foundations laid during the first project year, 2025 marked a year of consolidation, strategic improvements, and impactful outreach across Europe's scientific, medical, and civil society communities. A major milestone was the substantial update of the ARTEMIs website, which underwent structural, visual, and content-based enhancements to ensure clearer navigation, improved accessibility, and higher-quality information for all stakeholders. The Patients' Corner was enriched to further embed patient perspectives at the heart of the project. Updated sections on use cases, and events contributed to a more coherent and comprehensive online presence.

Taken together, the communication and dissemination achievements of 2025 have increased the project's visibility, strengthened engagement with key communities, and ensured that the project's progress is communicated clearly and consistently. Going forward, ARTEMIs is well-equipped to continue expanding its outreach, supporting transparency, and ensuring that its

innovations reach patients, clinicians, and researchers who stand to benefit most from personalised, AI-driven liver disease management.

## 5. FUTURE WORK

*-Project website and social media:* ongoing updates to the project website and social media (Bluesky and LinkedIn) are planned in the next twelve months and after, with the goal of sharing monthly posts about new events, publications, interviews, and contributions to open science.

*-Public engagement and layperson events:* ELPA is tasked with organizing two public-facing events targeted at patients and the broader society to communicate project achievements and expected impacts. These events will include interviews with principal investigators and aim to simplify project goals for public understanding.

*-Scientific publications and contributions to scientific conferences:* scientific partners will continue with their active participation in international conferences, and their activity in the elaboration of scientific articles will progressively intensify as first scientific results are delivered. The aim is to disseminate their findings to the research community in academia and industry.

*-Annual communication report (Deliverable D1.6, Month 36):* a record of all dissemination and communication actions conducted in the first 36 months, along with an updated plan for future activities will be released at the end of 2026. Those reports will be updated after each year until the end of the project.

The expected outcomes of this communication and dissemination strategy are: to increase public awareness by enhancing visibility through social media, press releases, and events, and through events and informative content, the project aims to engage patients and medical practitioners, promoting the potential benefits of the ARTEMIs platform for personalized disease management.